CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Juvéderm® VOLIFT™ with Lidocainedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03796728
NCT03796728Phase 4Completed
CompareCT.gov

LIPS: A Prospective, Open-label Study to Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for Lip Augmentation

Allergan·interventional·Posted Jan 8, 2019·Updated Jul 28, 2021

In Brief

A Phase 4 clinical trial evaluating Juvéderm® VOLIFT™ with Lidocaine for Lip Augmentation. Completed, enrolled 60 participants across 4 sites in 2 countries.

Detailed Summary

This is an open-label, multi-center, study where eligible participants will undergo treatment with Juvéderm® VOLIFT™ with Lidocaine injected into the lips for lip augmentation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLip Augmentation
CountriesPortugal, United Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedJan 8, 2019
Enrollment StartDec 19, 2018
Primary CompletionJun 9, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.5 years ago

Interventions

Juvéderm® VOLIFT™ with Lidocainedevice

Injectable gel that is a sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogeneous gel implant (dermal filler).